Literature DB >> 2648254

Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation.

V M Richon1, R G Ramsay, R A Rifkind, P A Marks.   

Abstract

The induction of murine erythroleukemia cells (MELC) to terminal differentiation by hexamethylene bisacetamide (HMBA) is accompanied by changes in the levels of c-myb and c-myc mRNA, and in p53 protein levels. We simultaneously examined the effects of HMBA on modulation of c-myb, c-myc and p53 mRNA and protein levels, and examined the relationship between these changes and commitment to terminal cell division. In MELC cultured with HMBA, c-myb protein levels paralleled c-myb mRNA levels except at 24h, when the protein level was equivalent to the level in control cultures, whereas the mRNA had decreased. The c-myc protein paralleled c-myc mRNA throughout induction. The p53 mRNA and protein behaved in a discordant fashion. The p53 protein decreased to very low levels between 4 and 8 h and remained low, while the mRNA, which initially decreased, reaccumulated by 24 and 48 h. Transfer of MELC after 12 to 48 h of culture with HMBA to medium without inducer resulted in rapid (less than 3 h) reaccumulation of the c-myb mRNA, c-myb protein, and p53 protein, and cessation of recruitment of cells to commitment. Cells already induced to commit to terminal differentiation continued to express the differentiated phenotype.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2648254

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

Authors:  V M Richon; Y Webb; R Merger; T Sheppard; B Jursic; L Ngo; F Civoli; R Breslow; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 2.  Relationship of eukaryotic DNA replication to committed gene expression: general theory for gene control.

Authors:  L P Villarreal
Journal:  Microbiol Rev       Date:  1991-09

3.  Enhanced translation and increased turnover of c-myc proteins occur during differentiation of murine erythroleukemia cells.

Authors:  G D Spotts; S R Hann
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

4.  Alteration in p53 modulates glial proteins in human glial tumour cells.

Authors:  H S U; A Banaie; L Rigby; J Chen; H Meltzer
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

5.  Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells.

Authors:  J J Ryan; R Danish; C A Gottlieb; M F Clarke
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

6.  Transactivation of erythroid transcription factor GATA-1 by a myb-ets-containing retrovirus.

Authors:  R E Aurigemma; D G Blair; S K Ruscetti
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  Hexamethylenebisacetamide-induced erythroleukemia cell differentiation involves modulation of events required for cell cycle progression through G1.

Authors:  H Kiyokawa; V M Richon; G Venta-Perez; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

8.  Conversion of differentiation inducer resistance to differentiation inducer sensitivity in erythroleukemia cells.

Authors:  J Michaeli; Y B Lebedev; V M Richon; Z X Chen; P A Marks; R A Rifkind
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

Review 9.  Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.

Authors:  Claudia P Miller; Melissa M Singh; Nilsa Rivera-Del Valle; Christa A Manton; Joya Chandra
Journal:  J Biomed Biotechnol       Date:  2011-06-28

10.  p53 gene mRNA expression and chromosome 17p allele loss in breast cancer.

Authors:  A M Thompson; C M Steel; U Chetty; R A Hawkins; W R Miller; D C Carter; A P Forrest; H J Evans
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.